Hightide Therapeutics Inc (HK:2511) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HighTide Therapeutics Inc. has successfully completed patient enrollment for its Phase III clinical trial comparing HTD1801 with dapagliflozin for treating Type 2 Diabetes Mellitus. This trial, which involves 358 participants, aims to assess the effectiveness of HTD1801 in improving glucose metabolism and insulin resistance. Final results are anticipated in 2025, marking a significant milestone in the company’s development of innovative therapies for metabolic diseases.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.